The Chemical Engineer5h
FDA approves ‘first’ of new class of non-addictive drugs for severe pain
The US Food and Drug Administration (FDA) has approved a non-opioid drug for severe post-surgical pain, which could “redefine ...
News97h
New non-opioid drug offers hope for pain management
Journavx, a new non-opioid pain medication, offers a safer alternative for managing acute pain while reducing the risk of ...
Interim Two-Year Follow-Up Data from the VenoValve(R) U.S. Pivotal Trial to be Presented Today at the VESS 2025 Annual Winter Meeting
Two-year follow-up data from 34 subjects in the VenoValve pivotal trial show sustained clinical improvement and continued patient benefit, from 12 months to 24 months.